A trial looking at a drug called barasertib for people with lymphoma

Cancer type:

Blood cancers
High grade lymphoma
Non-Hodgkin lymphoma




Phase 2

This trial was for people with diffuse large B cell lymphoma (DLBCL) that had continued to grow or came back after chemotherapy.

More about this trial

Doctors usually treat DLBCL with chemotherapy. But if the lymphoma continues to grow or comes back it is more difficult to treat.

Barasertib is a drug that blocks substances (enzymes Open a glossary item) called aurora kinases. Cells need these enzymes to grow and divide. Blocking them may stop the lymphoma growing.

Barasertib has been used for other types of cancer. But doctors weren’t sure how well it would work for lymphoma.

The aims of this trial were to

  • See if barasertib helped people with DLBCL that had continued to grow or came back after chemotherapy
  • Look at the side effects of barasertib

Summary of results

The trial team found that barasertib could help people with diffuse large B cell lymphoma (DLBCL). 

This was a phase 2 trial.15 people joined the trial.

After their 2nd treatment a PET-CT scan was done to see how well the lymphoma had responded. For 3 people, there was either no sign of their lymphoma (a complete response) or it had shrunk in size (a partial response). For the majority of people their lymphoma stayed the same.

The worst side effects were

  • A drop in blood cells
  • Feeling or being sick
  • Diarrhoea
  • Tiredness
  • Sore mouth

The team concluded this trial showed that targeting an aurora kinase enzyme using barasertib works as a treatment for DLBCL. But because of the limited response of DLBCL to barasertib, it is unlikely to be used by itself. Further trials using barasertib aren’t been planned by the team as it is difficult to give. Also there are other promising drugs to develop.

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Chris Hatton

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Oxford Biomedical Research Centre
Oxford University Hospitals NHS Trust

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think